JP2016501010A - 体重増加及び/又はインスリン抵抗性を低減させるためのラクトバチルスラムノサス株の使用 - Google Patents
体重増加及び/又はインスリン抵抗性を低減させるためのラクトバチルスラムノサス株の使用 Download PDFInfo
- Publication number
- JP2016501010A JP2016501010A JP2015540986A JP2015540986A JP2016501010A JP 2016501010 A JP2016501010 A JP 2016501010A JP 2015540986 A JP2015540986 A JP 2015540986A JP 2015540986 A JP2015540986 A JP 2015540986A JP 2016501010 A JP2016501010 A JP 2016501010A
- Authority
- JP
- Japan
- Prior art keywords
- food
- insulin resistance
- strain
- weight gain
- lactobacillus rhamnosus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 32
- 206010022489 Insulin Resistance Diseases 0.000 title claims abstract description 30
- 235000019786 weight gain Nutrition 0.000 title claims abstract description 21
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 20
- 230000004584 weight gain Effects 0.000 title claims abstract description 20
- 235000013305 food Nutrition 0.000 claims abstract description 29
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims abstract description 29
- 208000008589 Obesity Diseases 0.000 claims abstract description 19
- 235000020824 obesity Nutrition 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 206010033307 Overweight Diseases 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 235000020825 overweight Nutrition 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 16
- 239000013589 supplement Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 235000014048 cultured milk product Nutrition 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 235000009200 high fat diet Nutrition 0.000 description 34
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 239000006041 probiotic Substances 0.000 description 18
- 235000018291 probiotics Nutrition 0.000 description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 239000008103 glucose Substances 0.000 description 15
- 230000000529 probiotic effect Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 239000003925 fat Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 229940009289 bifidobacterium lactis Drugs 0.000 description 6
- 235000019577 caloric intake Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 235000012631 food intake Nutrition 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 238000007410 oral glucose tolerance test Methods 0.000 description 5
- 238000010162 Tukey test Methods 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 230000003579 anti-obesity Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102100025674 Angiopoietin-related protein 4 Human genes 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241000186606 Lactobacillus gasseri Species 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000006371 metabolic abnormality Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012175 pyrosequencing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000693076 Homo sapiens Angiopoietin-related protein 4 Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000116699 Lactobacillus acidophilus NCFM Species 0.000 description 1
- 235000009195 Lactobacillus acidophilus NCFM Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 241000186612 Lactobacillus sakei Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940108924 conjugated linoleic acid Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000013229 diet-induced obese mouse Methods 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000007412 host metabolism Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019722 synbiotics Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Abstract
Description
1980年から、世界中の肥満人口は倍以上に増加している。2008年には、14億人を超える成人(20歳以上)が過体重であった。このうち2億人を超える男性及びほぼ3億人の女性が肥満であった。
脂肪蓄積及び体重の個体間差は、遺伝的背景、健康状態、薬物療法又は年齢のような種々のファクターと相互に関連付けられ得るが、肥満及びインスリン抵抗性が現在頻発している主原因の1つは、日常生活における身体活動の減少と、高脂肪高スクロース食物に富む欧米スタイルの食物(diet)との組合せであることが広く受け容れられている。
したがって、本発明の1つの目的は、対象者における食物誘因体重増加及び/又は食物誘因インスリン抵抗性を低減させるための、ラクトバチルス ラムノサスCNCM I-3690株又は該株を含む組成物の使用である。
食物誘因体重増加及び/又は食物誘因インスリン抵抗性に起因する病状の例は、過体重、肥満及び関連する疾患、例えば、2型糖尿病、非アルコール性脂肪肝疾患(NAFLD)、高血圧などである。
ラクトバチルス ラムノサスCNCM I-3690株は、生存していてもしていなくてもよい菌全体の形態で使用することができる。或いは、この株は、細菌溶解物の形態で又は細菌画分の形態で使用することができる。
菌が生菌の形態であるとき、組成物は、乾燥重量1gあたり、代表的には105〜1013コロニー形成単位(cfu)、好ましくは少なくとも106cfu、より好ましくは少なくとも107cfu、更により好ましくは少なくとも108cfu、最も好ましくは少なくとも109cfuを含んでなってもよい。これは、液体組成物の場合、一般には104〜1012コロニー形成単位(cfu)、好ましくは少なくとも105cfu、より好ましくは少なくとも106cfu、更により好ましくは少なくとも107cfu、最も好ましくは少なくとも109cfu/mlに相当する。
本発明における使用に適切な組成物の他の例は、医薬組成物である。
本発明は、脂質貯蔵に対する菌株CNCM I-3690の効果を説明する実施例に言及する以下の更なる説明からより明確に理解されよう。
材料及び方法
C57BL/6Jマウス(雄、12週齢)を、下記の異なる処置を施す3群(1群あたり8マウス)に分けた:
A群:高脂肪食(34.9%脂肪含有、5.24kcal/g、Research Diets, Inc.[New Brunswick, NJ]社製)(HFD);
B群:高脂肪食+プロバイオティクス株エル.ラムノサスCNCM I3690(108CFU/マウス/日)(HFD+CNCM I-3690);
C群:高脂肪食+比較としてのプロバイオティクス株ビフィドバクテリウム ラクティスB420(Danisco)(108CFU/マウス/日)(HFD+ビー.ラクティスB420)(この株は、高脂肪食に関連する代謝に対する有害効果を低減させることが以前に報告された(AMARら,2011,前出);
D群:通常固形飼料(4.3%脂肪含有、3.85kcal/g、Research Diets, Inc.[New Brunswick, NJ]社製)(NC)。
動物の処置を12週間継続し、その間、各マウスの体重及びケージごとの摂食量を週に2回測定した。月に1回、代謝ケージを用いて新鮮な糞便及び尿サンプルを採集し、後の分析のために即座に−80℃で保存した。
試験の終時に、5時間の絶食後、眼窩静脈叢から採血し、15分間4℃で3000rpmの遠心分離により血清を単離した。全ての動物を頸椎脱臼により犠牲にした。犠牲後、精巣上体の脂肪体、肝臓及び空腸を摘出し、秤量し、直ぐにRNALater(Ambion)中で維持した。
結果を図1に示す。A:体重増加;B:空腹時血中グルコースレベル(FBG);C:空腹時インスリンレベル(FINS);D:インスリン抵抗性の恒常性評価(HOMA-IR)指数;E:経口グルコース負荷試験(OGTT)曲線、F:OGTTの曲線下面積(AUC)。データは平均±S.E.M.として示す。** p<0.01、* p<0.05(対HFD群)、## p<0.01、# p<0.05(対NC群)(SPSSにおける一元ANOVAに続くチューキーのポストホック検定による)。
Claims (6)
- 対象者における食物誘因体重増加及び/又は食物誘因インスリン抵抗性を低減させるために使用するラクトバチルス ラムノサスCNCM I-3690株。
- 食物誘因体重増加及び/又は食物誘因インスリン抵抗性に起因する病状の治療、予防又は緩和に使用する、請求項1に記載のラクトバチルス ラムノサスCNCM I-3690株。
- 前記病状が過体重、肥満及び肥満関連疾患から選択される、請求項1又は2に記載のラクトバチルス ラムノサスCNCM I-3690株。
- 経口投与可能な組成物に含まれている、請求項1〜3のいずれか1項に記載のラクトバチルス ラムノサスCNCM I-3690株。
- 前記組成物が食品又は補助食品である、請求項4に記載のラクトバチルス ラムノサスCNCM I-3690株。
- 前記食品が発酵乳製品である、請求項5に記載のラクトバチルス ラムノサスCNCM I-3690株。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2012/084462 WO2014071633A1 (en) | 2012-11-12 | 2012-11-12 | Use of lactobacillus rhamnosus strain for reducing weight gain and/or insulin resistance |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2016501010A true JP2016501010A (ja) | 2016-01-18 |
Family
ID=50683962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015540986A Pending JP2016501010A (ja) | 2012-11-12 | 2012-11-12 | 体重増加及び/又はインスリン抵抗性を低減させるためのラクトバチルスラムノサス株の使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US10022407B2 (ja) |
EP (1) | EP2917335B1 (ja) |
JP (1) | JP2016501010A (ja) |
CN (1) | CN104870632A (ja) |
AR (1) | AR093426A1 (ja) |
BR (1) | BR112015010698A2 (ja) |
CA (1) | CA2891618A1 (ja) |
ES (1) | ES2675309T3 (ja) |
MX (1) | MX2015005898A (ja) |
RU (1) | RU2015122748A (ja) |
WO (1) | WO2014071633A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019528763A (ja) * | 2016-09-30 | 2019-10-17 | シージェイ チェイルジェダン コーポレイション | 新規なラクトバチルス・サケイ及びそれを含む組成物 |
JP2020532315A (ja) * | 2017-09-06 | 2020-11-12 | ゲノム アンド カンパニー | ラクトバチルス・ラムノサスlm1019菌株およびこれを含む肥満または糖尿病の予防および治療用の組成物 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200155622A1 (en) * | 2017-05-22 | 2020-05-21 | Compagnie Gervais Danone | Compositions and methods for decreasing a population of bilophila wadsworthia or inhibiting the growth thereof |
WO2019199094A1 (ko) * | 2018-04-11 | 2019-10-17 | 한국생명공학연구원 | 비만의 예방 또는 치료 효과를 가지는 신규 비피도박테리움 롱검 균주 또는 락토바실러스 람노서스 균주 및 이의 용도 |
WO2020006663A1 (zh) * | 2018-07-02 | 2020-01-09 | 葡萄王生技股份有限公司 | 用于改善代谢症候群的新颖副干酪乳杆菌 gks6、其培养基、培养方法、用途、医药组合物及可食用组合物 |
CN109757730B (zh) * | 2019-01-31 | 2021-06-04 | 山东环亿生物科技有限公司 | 一种具有降血脂、血压以及血糖的组合物及其制备方法 |
CN113018319A (zh) * | 2021-01-21 | 2021-06-25 | 中南大学 | 一种用于缓解因长期低剂量辐射暴露所致胰岛素抵抗的复合菌剂及其应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003252770A (ja) * | 2002-02-28 | 2003-09-10 | Snow Brand Milk Prod Co Ltd | 糖尿病合併症予防・改善・治療剤 |
US20050186189A1 (en) * | 2004-02-19 | 2005-08-25 | Genmont Biotech Inc. | Novel microorganism strain GM-020 of Lactobacillus rhamnosus and its use for treating obesity |
US20100178281A1 (en) * | 2007-07-05 | 2010-07-15 | Nestec S.A. | Supplemention of maternal diet |
EP2216035A1 (en) * | 2009-02-10 | 2010-08-11 | Nestec S.A. | Lactobacillus rhamnosus CNCM I-4096 and weight control |
EP2216036A1 (en) * | 2009-02-10 | 2010-08-11 | Nestec S.A. | Lactobacillus rhamnosus NCC4007, a probiotic mixture and weight control |
WO2010130785A2 (en) * | 2009-05-12 | 2010-11-18 | Valio Ltd | Novel use of probiotics |
JP2011515085A (ja) * | 2008-03-19 | 2011-05-19 | コンパニ・ジェルベ・ダノン | ラクトバチルス・ラムノサス株 |
EP2407532A2 (en) * | 2009-03-10 | 2012-01-18 | Hero España, S.A. | Isolation, identification and characterisation of strains with probiotic activity, from faeces of infants fed exclusively with breast milk |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2604689E (pt) | 2005-07-26 | 2015-03-09 | Nestec Ltd | Agente anti-obesidade e alimento anti-obesidade |
ES2693584T3 (es) * | 2006-01-27 | 2018-12-12 | Dupont Nutrition Biosciences Aps | Uso de microorganismos probióticos para el tratamiento y prevención de obesidad y trastornos relacionados |
EP2022502A1 (en) | 2007-08-10 | 2009-02-11 | Nestec S.A. | Lactobacillus rhamnosus and weight control |
EA024911B1 (ru) * | 2010-01-08 | 2016-11-30 | Компани Жервэ Данон | Лактобациллы с антиоксидантным действием |
-
2012
- 2012-11-12 CA CA2891618A patent/CA2891618A1/en not_active Abandoned
- 2012-11-12 JP JP2015540986A patent/JP2016501010A/ja active Pending
- 2012-11-12 CN CN201280077003.4A patent/CN104870632A/zh active Pending
- 2012-11-12 ES ES12888054.9T patent/ES2675309T3/es active Active
- 2012-11-12 RU RU2015122748A patent/RU2015122748A/ru not_active Application Discontinuation
- 2012-11-12 US US14/442,040 patent/US10022407B2/en active Active
- 2012-11-12 EP EP12888054.9A patent/EP2917335B1/en active Active
- 2012-11-12 WO PCT/CN2012/084462 patent/WO2014071633A1/en active Application Filing
- 2012-11-12 MX MX2015005898A patent/MX2015005898A/es unknown
- 2012-11-12 BR BR112015010698A patent/BR112015010698A2/pt not_active IP Right Cessation
-
2013
- 2013-11-08 AR ARP130104121A patent/AR093426A1/es unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003252770A (ja) * | 2002-02-28 | 2003-09-10 | Snow Brand Milk Prod Co Ltd | 糖尿病合併症予防・改善・治療剤 |
US20050186189A1 (en) * | 2004-02-19 | 2005-08-25 | Genmont Biotech Inc. | Novel microorganism strain GM-020 of Lactobacillus rhamnosus and its use for treating obesity |
US20100178281A1 (en) * | 2007-07-05 | 2010-07-15 | Nestec S.A. | Supplemention of maternal diet |
JP2011515085A (ja) * | 2008-03-19 | 2011-05-19 | コンパニ・ジェルベ・ダノン | ラクトバチルス・ラムノサス株 |
EP2216035A1 (en) * | 2009-02-10 | 2010-08-11 | Nestec S.A. | Lactobacillus rhamnosus CNCM I-4096 and weight control |
EP2216036A1 (en) * | 2009-02-10 | 2010-08-11 | Nestec S.A. | Lactobacillus rhamnosus NCC4007, a probiotic mixture and weight control |
EP2407532A2 (en) * | 2009-03-10 | 2012-01-18 | Hero España, S.A. | Isolation, identification and characterisation of strains with probiotic activity, from faeces of infants fed exclusively with breast milk |
WO2010130785A2 (en) * | 2009-05-12 | 2010-11-18 | Valio Ltd | Novel use of probiotics |
Non-Patent Citations (2)
Title |
---|
BIOCHIMICA ET BIOPHYSICA ACTA , vol. Vol. 1761, Issue 7, JPN6016033223, 20 May 2006 (2006-05-20), pages 736 - 744, ISSN: 0003388704 * |
田渕三保子 他: "Lactobacillus rhamnosus GG摂取がラット食後血糖値に及ぼす影響", MILK SCIENCE, vol. 54, no. 1, JPN6016033221, 2005, pages 17 - 21, ISSN: 0003388703 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019528763A (ja) * | 2016-09-30 | 2019-10-17 | シージェイ チェイルジェダン コーポレイション | 新規なラクトバチルス・サケイ及びそれを含む組成物 |
JP2020532315A (ja) * | 2017-09-06 | 2020-11-12 | ゲノム アンド カンパニー | ラクトバチルス・ラムノサスlm1019菌株およびこれを含む肥満または糖尿病の予防および治療用の組成物 |
Also Published As
Publication number | Publication date |
---|---|
RU2015122748A (ru) | 2017-01-10 |
EP2917335B1 (en) | 2018-04-04 |
US10022407B2 (en) | 2018-07-17 |
CA2891618A1 (en) | 2014-05-15 |
AR093426A1 (es) | 2015-06-10 |
US20150297646A1 (en) | 2015-10-22 |
ES2675309T3 (es) | 2018-07-10 |
WO2014071633A1 (en) | 2014-05-15 |
MX2015005898A (es) | 2016-02-05 |
EP2917335A1 (en) | 2015-09-16 |
EP2917335A4 (en) | 2016-06-29 |
BR112015010698A2 (pt) | 2017-07-11 |
CN104870632A (zh) | 2015-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11273188B2 (en) | Strain having ability to inhibit obesity and pharmaceutical composition containing same | |
EP2898061B1 (en) | Probiotic compositions for the treatment of obesity and obesity-related conditions | |
Hoesl et al. | The probiotic approach: an alternative treatment option in urology | |
EP2917335B1 (en) | Use of lactobacillus rhamnosus strain for reducing weight gain and/or insulin resistance | |
JP6101818B2 (ja) | 体重増加及びインスリン抵抗性を治療又は予防するためのビフィドバクテリウムアニマリスの使用 | |
KR102146429B1 (ko) | 비피도박테리움 아니말리스 아종 아니말리스 균주 | |
EP3182841A1 (en) | Prebiotics for reducing the risk of obesity later in life | |
Liu et al. | Evidence from comparative genomic analyses indicating that Lactobacillus-mediated irritable bowel syndrome alleviation is mediated by conjugated linoleic acid synthesis | |
US9855304B2 (en) | Lactobacillus rhamnosus strain for reducing body fat accumulation | |
JP2010132580A (ja) | 脂質代謝改善効果を有する乳酸菌 | |
RU2771744C2 (ru) | Синбиотическая композиция для профилактики метаболических нарушений | |
İŞGÜZAR et al. | Effects of Gut Microbiota and Probiotics on Obesity | |
CN116509903A (zh) | 一种增强免疫功能的合生元组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151028 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160830 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170117 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170404 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20171121 |